Clinical Trial Update: Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NMIBC Patients [NA]

View source ↗

Summary

A pilot study evaluating the clinical response to intravesical Mitomycin-C in a hydrogel formulation (TC-3) for non-muscle invasive bladder cancer; the trial ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• Mitomycin-C (mitomycin C)

Snippet

Sponsor: UroGen Pharma Ltd. | Conditions: Urinary Bladder Neoplasms, Urologic Neoplasms | NA | Status: COMPLETED